Tags

Type your tag names separated by a space and hit enter

Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
Cytotherapy. 2004; 6(6):533-42.C

Abstract

BACKGROUND

The aim of this study was to investigate preservation of anti-leukemic activity and protection from opportunistic infections after transplantation of allogeneic + cells in patients with hematologic malignancies and bad prognosis. Methods Thirty-three patients [median age 42 years, range 23-55 years, diagnosis AML/myelodysplastic syndrome (MDS) 14, ALL nine, CML seven and multiple myeloma (MM) three] received myeloablative conditioning followed by infusion of selected CD34+ cells from matched unrelated donors (31) or HLA-identical siblings (two). Early donor lymphocyte infusions (DLI; 0.5 and 1.0 x 10(6) CD3+ cells/kg) were given while patients were on immunosuppressive therapy.

RESULTS

Ninety-seven per cent of patients engrafted and 24 of 29 patients surviving more than 30 days received at least one pre-emptive DLI. Three patients (10%) developed acute (a)GvHD (two grade I-II, one grade III-IV) spontaneously, and 16 patients (67%) developed aGvHD after DLI (12 grade I-II, four grade III-IV). Eight of 24 evaluable patients developed chronic (c)GvHD (33%, six limited, two extensive). After a median follow-up of 590 days (range 138-1610 days) 18 patients were alive (55%), 16 in complete remission (CR), one in hematologic and one in molecular relapse. Seven patients died after relapse (21%) and eight died from transplantation-related causes (24%). Patients with myeloid malignancies had a significantly better survival than patients with ALL or MM (74%+/-10 vs. 30%+/-13, P<0.05).

DISCUSSION

Early pre-emptive low-dose DLI following transplantation of selected CD34+ cells from unrelated donors after myeloablative conditioning is feasible and effective without undue toxicity, especially in patients with myeloid malignancies.

Authors+Show Affiliations

Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University Düsseldorf Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15764020

Citation

Kobbe, G, et al. "Transplantation of Allogeneic CD34+-selected Cells Followed By Early T-cell Add-backs: Favorable Results in Acute and Chronic Myeloid Leukemia." Cytotherapy, vol. 6, no. 6, 2004, pp. 533-42.
Kobbe G, Fenk R, Neumann F, et al. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy. 2004;6(6):533-42.
Kobbe, G., Fenk, R., Neumann, F., Bernhardt, A., Steidl, U., Kondakci, M., Graef, T., Aivado, M., Vaupel, M., Huenerlituerkoglu, A. N., Kronenwett, R., Pape, H., Hildebrand, B., Germing, U., & Haas, R. (2004). Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy, 6(6), 533-42.
Kobbe G, et al. Transplantation of Allogeneic CD34+-selected Cells Followed By Early T-cell Add-backs: Favorable Results in Acute and Chronic Myeloid Leukemia. Cytotherapy. 2004;6(6):533-42. PubMed PMID: 15764020.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. AU - Kobbe,G, AU - Fenk,R, AU - Neumann,F, AU - Bernhardt,A, AU - Steidl,U, AU - Kondakci,M, AU - Graef,T, AU - Aivado,M, AU - Vaupel,M, AU - Huenerlituerkoglu,A-N, AU - Kronenwett,R, AU - Pape,H, AU - Hildebrand,B, AU - Germing,U, AU - Haas,R, PY - 2005/3/15/pubmed PY - 2005/9/17/medline PY - 2005/3/15/entrez SP - 533 EP - 42 JF - Cytotherapy JO - Cytotherapy VL - 6 IS - 6 N2 - BACKGROUND: The aim of this study was to investigate preservation of anti-leukemic activity and protection from opportunistic infections after transplantation of allogeneic + cells in patients with hematologic malignancies and bad prognosis. Methods Thirty-three patients [median age 42 years, range 23-55 years, diagnosis AML/myelodysplastic syndrome (MDS) 14, ALL nine, CML seven and multiple myeloma (MM) three] received myeloablative conditioning followed by infusion of selected CD34+ cells from matched unrelated donors (31) or HLA-identical siblings (two). Early donor lymphocyte infusions (DLI; 0.5 and 1.0 x 10(6) CD3+ cells/kg) were given while patients were on immunosuppressive therapy. RESULTS: Ninety-seven per cent of patients engrafted and 24 of 29 patients surviving more than 30 days received at least one pre-emptive DLI. Three patients (10%) developed acute (a)GvHD (two grade I-II, one grade III-IV) spontaneously, and 16 patients (67%) developed aGvHD after DLI (12 grade I-II, four grade III-IV). Eight of 24 evaluable patients developed chronic (c)GvHD (33%, six limited, two extensive). After a median follow-up of 590 days (range 138-1610 days) 18 patients were alive (55%), 16 in complete remission (CR), one in hematologic and one in molecular relapse. Seven patients died after relapse (21%) and eight died from transplantation-related causes (24%). Patients with myeloid malignancies had a significantly better survival than patients with ALL or MM (74%+/-10 vs. 30%+/-13, P<0.05). DISCUSSION: Early pre-emptive low-dose DLI following transplantation of selected CD34+ cells from unrelated donors after myeloablative conditioning is feasible and effective without undue toxicity, especially in patients with myeloid malignancies. SN - 1465-3249 UR - https://www.unboundmedicine.com/medline/citation/15764020/Transplantation_of_allogeneic_CD34+_selected_cells_followed_by_early_T_cell_add_backs:_favorable_results_in_acute_and_chronic_myeloid_leukemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/X8NWKX0AC5JXK9Q4 DB - PRIME DP - Unbound Medicine ER -